Orbit Genomics® is redefining precision medicine with OrbiSeq™, the first AI-powered platform that accurately analyzes short tandem repeats—dynamic, stress-responsive DNA sequences that reveal both inherited disease risk and risk acquired from living. Unlike traditional tests focused on static genetic mutations (SNPs), OrbiSeq delivers a personalized, actionable view of health and disease trajectory.

Built on more than two decades of NIH-funded research, the OrbiSeq technology platform unlocks the genomic signals missed by standard sequencing, with validated applications in early disease diagnosis, companion diagnostics, therapeutic target discovery, and aging-related risk. With products in development across cancer, cardiovascular, neurological, and inflammatory diseases, Orbit Genomics is unlocking the missing piece of the genomics puzzle.